Log in to search using one of your social media accounts:

 

UCLA receives $8.4 million NIH grant to help liver transplant recipients stay healthier longer

UCLA has received an $8.4 million grant from the National Institutes of Health to research ways to help donated livers last longer and improve outcomes for transplant recipients.The five-year grant is the fourth in a series from the NIH to the Dumont –UCLA Transplant Center to develop medications to prevent the body from rejecting a transplanted liver and help patients live longer, healthier lives. The grants have totaled more than $13 million.The initiative is headed by Dr. Jerzy Kupiec-Weglinski, the Paul I. Terasaki Chair in Surgery and vice chair of research at the Department of Surgery at the David Geffen School of Medicine at UCLA. The project brings together the expertise and experience of researchers from the UCLA departments of surgery, pathology and laboratory medicine, and microbiology, immunology and molecular genetics.UCLA HealthDr. Jerzy Kupiec-Weglinski“There are less than 10 program project grants in the country funded by the NIH that are related to organ transplantation, so this is a big deal,” Kupiec-Weglinski said. “Through this project, we believe we will develop novel therapeutic strategies that can be directly applied in transplant pa tients.”  Around 6,000 liver transplant surgeries are performed every year in the U.S., and UCLA ’s liver transplant program was the nation’s fourth busiest last year, according to the United Network for Organ Sharing. UCLA doctors performed 161 liver transplants in 2...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

Condition:   Cirrhosis, Liver Intervention:   Other: intestinal microbiota transplant Sponsor:   Zhongshan Hospital Xiamen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: Liver Transplantation - Category: Transplant Surgery Authors: Tags: Letters to the Editor Source Type: research
ConclusionsIn our early diagnosed cohort, the 9‐year survival with native liver was better than that reported in other studies. Approximately 15% of patients developed liver‐related disease complications, less than previously reported. The long‐term course of SC was negatively influenced by the presence of autoimmune features, but not by concomitant IBD.
Source: Hepatology Research - Category: Internal Medicine Authors: Tags: Original Article Source Type: research
Summary To examine mid‐term benefits on hepatic complications, extrahepatic clinical syndromes and quality of life associated with HCV cure; to review the few safety issues linked to oral direct‐acting antivirals (DAAs); and to discuss the potential population benefits of reducing the burden of HCV infection. DAAs cure HCV infection in more than 95% of patients. The halting of liver inflammation and fibrosis progression translates into both hepatic and extrahepatic benefits and reduces the need for liver transplantation. A reduction in the frequency of extrahepatic manifestations such as mixed cryoglobulinaemia and vas...
Source: Journal of Viral Hepatitis - Category: Infectious Diseases Authors: Tags: COMMISSIONED REVIEW Source Type: research
ConclusionsPenicillamine followed by zinc may be a safe and effective treatment in resource-constrained setting for symptomatic hepatic WD patients in all grades of baseline disease severity. Some patients with decompensated cirrhosis due to WD may be managed with medical treatment, avoiding liver transplantation.
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
ConclusionOur experience further highlights the challenges of LTBI screening prior to LT and suggests that QFT may be a poor predictor of active TB in higher risk pre‐transplant populations. Candidates should be screened as early as possible to optimize QFT performance, and local epidemiological data should be used to create institution‐specific screening protocols in areas with large populations from TB‐endemic regions. Management should consider TB risk factors, QFT, and imaging instead of reliance on QFT testing alone.
Source: Transplant Infectious Disease - Category: Transplant Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conclusions : Sufficient desensitization for ABO-I living donor liver transplantation can be achieved using rituximab alone. This desensitization strategy does not affect the isoagglutinin titers, ABO-I-related complications and patient survival.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
Abstract Background: Obesity is increasingly common before and after liver transplantation (LT), yet optimal management remains unclear. Aim: To analyze the long term outcomes for obese patients undergoing LT including a non‐invasive weight loss program and combined LT and sleeve gastrectomy (SG). Methods: Since 2006, all patients referred for LT with a body mass index (BMI) ≥35 kg/m2 were enrolled. Patients who achieved weight loss (BMI 3 years of follow‐up, while overall, a total of 29 patients underwent LT+SG. Patients in the LT cohort had less severe obesity at enrollment (40.0±2.7 vs. LT+SG cohort...
Source: Hepatology - Category: Internal Medicine Authors: Tags: Steatohepatitis and Metabolic Liver Disease Source Type: research
ConclusionsReadmissions within 30  days were common among patients with cirrhosis hospitalized in California. While hospital cirrhosis volume did not predict 30-day readmissions, liver transplant center status was protective of readmissions. Medically complicated patients with cirrhosis at hospitals without liver transplant centers may benefit from additional support to prevent readmission.
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Allergy & Immunology | Genetics | Grants | Laboratory Medicine | Learning | Liver | Liver Transplant | Microbiology | National Institutes of Health (NIH) | Pancreas | Pathology | Transplant Surgery | Transplants | Universities & Medical Training | Urology & Nephrology